Bepirovirsen: The first antisense oligonucleotide approved to achieve a functional cure for chronic hepatitis B
Drug Discoveries & Therapeutics · 31.10.2026 · 20 (5) · 397-399
DOI: 10.5582/ddt.2026.01064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 31.10.2026. Verfasst von Yueyi Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Oligonucleotides, Antisense. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Zitieren
APA
Sun, Y., & Gao, J. (2026). Bepirovirsen: The first antisense oligonucleotide approved to achieve a functional cure for chronic hepatitis B. Drug Discoveries & Therapeutics, 20(5), 397-399. https://doi.org/10.5582/ddt.2026.01064
Vancouver
Sun Y, Gao J. Bepirovirsen: The first antisense oligonucleotide approved to achieve a functional cure for chronic hepatitis B. Drug Discoveries & Therapeutics. 2026;20(5):397-399. doi:10.5582/ddt.2026.01064
BibTeX
@article{Sun2026,
author = {Sun, Yueyi and Gao, Jianjun},
title = {Bepirovirsen: The first antisense oligonucleotide approved to achieve a functional cure for chronic hepatitis B},
journal = {Drug Discoveries & Therapeutics},
year = {2026},
volume = {20},
number = {5},
pages = {397--399},
doi = {10.5582/ddt.2026.01064}
}
EUVIMED